This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Copenhagen, May 1, 2014 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) will host an R&D and business briefing for the investment community on Wednesday, 21 May in New York City. The meeting offers an opportunity to learn more about allergy immunotherapy and will highlight the recent advances and future potential for ALK's allergy immunotherapy business.
The agenda will introduce ALK as an emerging specialty pharmaceutical company with a global growth strategy, and will offer a broad introduction to allergy immunotherapy - a unique treatment of the underlying cause of allergic rhinitis and allergic asthma.
The meeting will focus on the growing opportunity for ALK's business in the US market following the recent FDA approvals for two sublingual allergy immunotherapy tablets,
GRASTEK (r) and RAGWITEK (tm), both licensed to Merck for commercialisation in North America. There will also be a dedicated session on the company's forthcoming sublingual allergy immunotherapy tablet for the most prevalent allergy in the world, house dust mite allergy.
The meeting will close with a look at opportunities in Japan and other international markets, as well as a summary of R&D efforts to globalise ALK's existing portfolio and to expand into treating allergic asthma.
The confirmed presenters include the international key opinion leader in allergy immunotherapy, Professor Moises Calderon, MD from Imperial College London, as well as key ALK executives:
Jens Bager: President and Chief Executive Officer
Henrik Jacobi: Executive Vice President, Research and Development
Jose A. Moreno Toscano: President, ALK North America
Per Plotnikof: Head of Investor Relations and Strategic Planning
Jens Bager, ALK's President and CEO, said:
"This meeting comes at an exciting time, following the FDA approvals for GRASTEK (r) and RAGWITEK (tm), the recent initiation of US Phase III trials for our house dust mite product, and positive results from a house dust mite Phase III trial in Japan. In addition, our newly announced collaboration with Eddingpharm in China illustrates that we are intent on further international expansion and growth. We look forward to telling you more about these developments and our plans for the future at our meeting in New York."
The meeting runs from 12.30-4.30pm and will be followed by an informal reception.